دورية أكاديمية
أعرض في EDS

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer.

التفاصيل البيبلوغرافية
العنوان: The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer.
المؤلفون: Schepisi G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Gianni C; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Palleschi M; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Bleve S; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Casadei C; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Lolli C; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Ridolfi L; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Martinelli G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy.
المصدر: Cancers [Cancers (Basel)] 2023 Mar 04; Vol. 15 (5). Date of Electronic Publication: 2023 Mar 04.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Breast cancer represents one of the most common tumor histologies. To date, based on the specific histotype, different therapeutic strategies, including immunotherapies, capable of prolonging survival are used. More recently, the astonishing results that were obtained from CAR-T cell therapy in haematological neoplasms led to the application of this new therapeutic strategy in solid tumors as well. Our article will deal with chimeric antigen receptor-based immunotherapy (CAR-T cell and CAR-M therapy) in breast cancer.
References: Clin Breast Cancer. 2013 Oct;13(5):378-84. (PMID: 23810431)
J Immunother Cancer. 2014 Aug 19;2:25. (PMID: 25197555)
Semin Oncol. 2021 Jun;48(3):208-225. (PMID: 34620502)
J Exp Clin Cancer Res. 2020 May 12;39(1):87. (PMID: 32398042)
Cell Death Dis. 2018 Feb 7;9(2):177. (PMID: 29415996)
Biotechnol Appl Biochem. 2014 Jul-Aug;61(4):376-84. (PMID: 24329807)
J Cancer. 2016 Jun 03;7(9):1095-104. (PMID: 27326253)
Blood. 2005 Sep 1;106(5):1544-51. (PMID: 15890688)
Science. 2000 Aug 18;289(5482):1197-202. (PMID: 10947988)
Cell Rep. 2019 May 28;27(9):2690-2708.e10. (PMID: 31141692)
Cell Death Dis. 2018 Feb 15;9(3):282. (PMID: 29449531)
Adv Cell Gene Ther. 2018 Sep;1(2):. (PMID: 30420973)
Cell Immunol. 2018 Sep;331:49-58. (PMID: 29935762)
Cell. 2017 Jun 29;170(1):142-157.e19. (PMID: 28648661)
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14710-5. (PMID: 25267626)
Cancers (Basel). 2021 Nov 29;13(23):. (PMID: 34885122)
Oncotarget. 2017 May 30;8(22):35656-35668. (PMID: 27374101)
Am J Cancer Res. 2019 Aug 01;9(8):1846-1856. (PMID: 31497363)
Front Immunol. 2018 Dec 03;9:2740. (PMID: 30559740)
Cell. 2010 Apr 2;141(1):39-51. (PMID: 20371344)
Mol Cancer Ther. 2017 Apr;16(4):681-693. (PMID: 28108597)
Front Immunol. 2018 Apr 23;9:827. (PMID: 29740438)
Cancer Immunol Res. 2013 Jul;1(1):43-53. (PMID: 24409448)
Ann Oncol. 2014 Mar;25(3):611-618. (PMID: 24401929)
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. (PMID: 34754128)
Ther Adv Med Oncol. 2019 Aug 14;11:1758835919866065. (PMID: 31452692)
Cell Prolif. 2020 Aug;53(8):e12858. (PMID: 32592435)
Front Immunol. 2021 Nov 24;12:783305. (PMID: 34899748)
Drug Dev Res. 2008;69(6):329-339. (PMID: 20628538)
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38. (PMID: 17440164)
J Immunother Cancer. 2021 Aug;9(8):. (PMID: 34462325)
Curr Opin Immunol. 2007 Apr;19(2):239-45. (PMID: 17291742)
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19. (PMID: 22128289)
J Oncol. 2022 Jan 13;2022:5179182. (PMID: 35069735)
Expert Opin Biol Ther. 2015;15(8):1145-54. (PMID: 25985798)
Oncotarget. 2018 Jun 22;9(48):28989-29006. (PMID: 29989029)
Am J Cancer Res. 2016 Aug 01;6(8):1609-23. (PMID: 27648353)
Crit Rev Biotechnol. 2022 Nov;42(7):1079-1098. (PMID: 34957875)
Nat Commun. 2021 Aug 11;12(1):4867. (PMID: 34381029)
Cancer Res. 2001 Sep 15;61(18):6649-55. (PMID: 11559528)
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416. (PMID: 28117416)
Nat Rev Cancer. 2019 Oct;19(10):568-586. (PMID: 31462760)
Cancer Res. 2010 Feb 15;70(4):1544-54. (PMID: 20145120)
Nat Biotechnol. 2002 Jan;20(1):70-5. (PMID: 11753365)
Front Mol Biosci. 2022 Jan 25;9:836417. (PMID: 35145999)
Cancer Discov. 2019 Apr;9(4):466-468. (PMID: 30936218)
Pathol Int. 2016 Sep;66(9):491-505. (PMID: 27444136)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Transl Oncol. 2018 Apr;11(2):311-329. (PMID: 29413765)
Front Immunol. 2019 Oct 11;10:2250. (PMID: 31681259)
Cancer Immunol Immunother. 2021 Mar;70(3):619-631. (PMID: 33025047)
CA Cancer J Clin. 2017 Nov;67(6):507-524. (PMID: 28961310)
Int J Oncol. 2006 Nov;29(5):1311-7. (PMID: 17016666)
PLoS One. 2016 Jun 16;11(6):e0157368. (PMID: 27310713)
Semin Cancer Biol. 2020 Oct;65:13-27. (PMID: 31362073)
Lancet Oncol. 2020 Jan;21(1):44-59. (PMID: 31786121)
Biomed Pharmacother. 2021 Jul;139:111605. (PMID: 33901872)
Annu Rev Immunol. 2019 Apr 26;37:145-171. (PMID: 30526160)
Breast Cancer Res Treat. 2012 Jun;133(2):799-804. (PMID: 22418702)
Exp Biol Med (Maywood). 2015 Aug;240(8):1087-98. (PMID: 25956686)
J Biol Chem. 2001 Apr 6;276(14):11007-15. (PMID: 11118434)
J Cancer Res Clin Oncol. 2021 Dec;147(12):3725-3734. (PMID: 34032893)
Elife. 2018 Jun 04;7:. (PMID: 29862966)
Mol Ther. 2010 Apr;18(4):843-51. (PMID: 20179677)
Cancer Res. 2018 Jan 15;78(2):489-500. (PMID: 29183891)
Blood. 2008 Aug 1;112(3):461-9. (PMID: 18650461)
Nat Rev Immunol. 2015 Nov;15(11):683-91. (PMID: 26449179)
PLoS One. 2014 Dec 15;9(12):e114900. (PMID: 25506917)
Endocr Rev. 2012 Aug;33(4):504-25. (PMID: 22577091)
J Hematol Oncol. 2020 Nov 11;13(1):153. (PMID: 33176869)
Int J Mol Sci. 2018 Jan 24;19(2):. (PMID: 29364163)
Mol Cancer Ther. 2014 Sep;13(9):2141-8. (PMID: 25139999)
PLoS One. 2012;7(8):e43174. (PMID: 22912819)
Front Oncol. 2022 Aug 08;12:882896. (PMID: 36003772)
Nat Biotechnol. 2020 Aug;38(8):947-953. (PMID: 32361713)
Clin Breast Cancer. 2021 Aug;21(4):302-308. (PMID: 33750642)
Front Immunol. 2018 Jan 10;8:1911. (PMID: 29375561)
Cancer Immunol Res. 2014 Apr;2(4):361-70. (PMID: 24764583)
Cells. 2020 Jul 22;9(8):. (PMID: 32707982)
Nat Methods. 2020 Jun;17(6):561. (PMID: 32499619)
Oncotarget. 2011 Dec;2(12):1227-43. (PMID: 22204844)
Cancer Res. 1992 Jun 15;52(12):3396-401. (PMID: 1596899)
Cancer Cell. 2021 Feb 8;39(2):193-208.e10. (PMID: 33357452)
J Exp Med. 2020 May 4;217(5):. (PMID: 32106283)
Oncol Rep. 2019 Feb;41(2):801-810. (PMID: 30483806)
Anticancer Res. 2012 Jun;32(6):2241-7. (PMID: 22641658)
Ann Oncol. 2001;12 Suppl 1:S3-8. (PMID: 11521719)
Cancer Microenviron. 2011 Aug;4(2):141-54. (PMID: 21909876)
Front Oncol. 2020 Jul 07;10:1000. (PMID: 32733795)
Nat Med. 2018 Mar;24(3):352-359. (PMID: 29400710)
Front Immunol. 2018 Nov 08;9:2593. (PMID: 30467505)
J Clin Invest. 1992 Nov;90(5):1984-91. (PMID: 1331178)
Breast Cancer Res Treat. 2009 May;115(2):423-8. (PMID: 18543098)
Aging (Albany NY). 2019 Dec 4;11(23):11054-11072. (PMID: 31804974)
J Hematol Oncol. 2019 Oct 29;12(1):111. (PMID: 31665051)
MAbs. 2015;7(2):303-10. (PMID: 25667985)
Anticancer Res. 2011 Oct;31(10):3417-22. (PMID: 21965755)
Front Cell Dev Biol. 2018 Aug 28;6:97. (PMID: 30211160)
Int J Mol Sci. 2021 Feb 28;22(5):. (PMID: 33670942)
Cancer Res. 2008 Jun 1;68(11):4360-8. (PMID: 18519697)
Trends Mol Med. 2014 Jun;20(6):332-42. (PMID: 24667139)
Clin Cancer Res. 2014 Feb 15;20(4):962-71. (PMID: 24334762)
Br J Cancer. 2019 Nov;121(10):837-845. (PMID: 31570753)
Cancer Treat Rev. 2018 Nov;70:178-189. (PMID: 30227299)
Front Immunol. 2022 Nov 22;13:1018786. (PMID: 36483567)
Oncoimmunology. 2019 Nov 7;9(1):1683345. (PMID: 32002293)
Lancet Oncol. 2018 Jan;19(1):40-50. (PMID: 29233559)
Expert Opin Biol Ther. 2021 Apr;21(4):473-486. (PMID: 33176519)
Front Immunol. 2019 May 24;10:1149. (PMID: 31178870)
Biomed Res Int. 2020 Jan 2;2020:4795171. (PMID: 31998790)
Haematologica. 2018 Sep;103(9):e424-e426. (PMID: 29703727)
Clin Cancer Res. 2020 Feb 1;26(3):657-668. (PMID: 31611282)
Oncotarget. 2017 Oct 27;8(61):103671-103681. (PMID: 29262592)
Clin Cancer Res. 2000 Aug;6(8):3056-61. (PMID: 10955784)
Cancer Res. 2014 Oct 1;74(19):5561-71. (PMID: 25228655)
Int J Cancer. 2006 Oct 1;119(7):1519-29. (PMID: 16671089)
Nat Rev Cancer. 2010 Jan;10(1):9-22. (PMID: 20029421)
Biomolecules. 2020 Feb 10;10(2):. (PMID: 32050611)
Br J Cancer. 2019 Jan;120(1):26-37. (PMID: 30413825)
Nat Med. 2003 Jun;9(6):669-76. (PMID: 12778165)
J Hematol Oncol. 2019 Jul 12;12(1):76. (PMID: 31300030)
Cancer Biol Med. 2020 May 15;17(2):293-306. (PMID: 32587770)
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52. (PMID: 17062691)
Genes Cancer. 2017 Mar;8(3-4):536-549. (PMID: 28680538)
Transl Lung Cancer Res. 2014 Dec;3(6):392-4. (PMID: 25806330)
Infect Immun. 1992 Jul;60(7):2893-9. (PMID: 1377184)
Nature. 2018 Jul;559(7714):405-409. (PMID: 29995861)
Semin Cancer Biol. 1999 Apr;9(2):67-81. (PMID: 10202129)
Clin Transl Immunology. 2020 May 03;9(5):e01135. (PMID: 32373345)
Cancer Cell. 2012 Feb 14;21(2):212-26. (PMID: 22340594)
Sci Transl Med. 2018 Oct 3;10(461):. (PMID: 30282693)
JCI Insight. 2019 Sep 19;4(18):. (PMID: 31415244)
Front Oncol. 2020 Sep 03;10:1658. (PMID: 33014830)
Cytotherapy. 2018 Jul;20(7):952-963. (PMID: 30180944)
Cancer Immunol Immunother. 2019 Mar;68(3):365-377. (PMID: 30523370)
Immunity. 2014 Jul 17;41(1):49-61. (PMID: 25035953)
J Hematol Oncol. 2018 Jul 6;11(1):92. (PMID: 29980239)
Cancer Discov. 2019 Apr;9(4):492-499. (PMID: 30630850)
Oncogene. 2010 Sep 23;29(38):5254-64. (PMID: 20603615)
Cancer Res. 2011 Sep 1;71(17):5697-706. (PMID: 21742772)
Int J Cancer. 2013 Nov 15;133(10):2483-92. (PMID: 23661285)
Nat Rev Cancer. 2004 Jan;4(1):71-8. (PMID: 14708027)
Cancer. 1998 Apr 15;82(8):1513-20. (PMID: 9554529)
Front Immunol. 2019 Apr 12;10:757. (PMID: 31031757)
Cancer Discov. 2013 Apr;3(4):388-98. (PMID: 23550147)
Cancer Immunol Res. 2017 Dec;5(12):1152-1161. (PMID: 29109077)
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. (PMID: 23882082)
Int J Mol Med. 2018 Oct;42(4):1771-1785. (PMID: 30015855)
Cell Microbiol. 2016 Apr;18(4):475-87. (PMID: 26880038)
Mol Ther. 2020 Nov 4;28(11):2320-2339. (PMID: 32979309)
PLoS One. 2012;7(3):e31127. (PMID: 22403610)
Nat Biotechnol. 2020 Feb;38(2):233-244. (PMID: 31907405)
Sci Rep. 2017 Oct 30;7(1):14366. (PMID: 29085043)
Methods Mol Biol. 2009;531:253-65. (PMID: 19347322)
J Pediatr Hematol Oncol. 2019 Apr;41(3):163-169. (PMID: 30897608)
Cancer. 2010 Mar 15;116(6):1526-34. (PMID: 20108344)
فهرسة مساهمة: Keywords: T cells; breast cancer; chimeric antigen receptor (CAR); immunotherapy; macrophages
تواريخ الأحداث: Date Created: 20230311 Latest Revision: 20230313
رمز التحديث: 20230313
مُعرف محوري في PubMed: PMC10000829
DOI: 10.3390/cancers15051597
PMID: 36900394
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15051597